BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32394479)

  • 1. Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
    Lu X; Paliogiannis P; Calvisi DF; Chen X
    Hepatology; 2021 Jan; 73 Suppl 1(Suppl 1):49-61. PubMed ID: 32394479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
    Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
    J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer.
    Wang C; Cigliano A; Delogu S; Armbruster J; Dombrowski F; Evert M; Chen X; Calvisi DF
    Cell Cycle; 2013 Jul; 12(13):1999-2010. PubMed ID: 23759595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hippocalcin-Like 1 blunts liver lipid metabolism to suppress tumorigenesis via directly targeting RUVBL1-mTOR signaling.
    Chen T; Yuan Z; Lei Z; Duan J; Xue J; Lu T; Yan G; Zhang L; Liu Y; Li Q; Zhang Y
    Theranostics; 2022; 12(17):7450-7464. PubMed ID: 36438486
    [No Abstract]   [Full Text] [Related]  

  • 5. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
    Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
    Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mTOR signalling pathway in human cancer.
    Pópulo H; Lopes JM; Soares P
    Int J Mol Sci; 2012; 13(2):1886-1918. PubMed ID: 22408430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of mTOR signaling affects cone function, cone structure and expression of cone specific proteins without affecting cone survival.
    Ma S; Venkatesh A; Langellotto F; Le YZ; Hall MN; Rüegg MA; Punzo C
    Exp Eye Res; 2015 Jun; 135():1-13. PubMed ID: 25887293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
    Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
    Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
    Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
    Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
    Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
    Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo.
    Xie Z; Wang J; Liu M; Chen D; Qiu C; Sun K
    PLoS One; 2017; 12(3):e0173252. PubMed ID: 28334043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.
    Willems L; Tamburini J; Chapuis N; Lacombe C; Mayeux P; Bouscary D
    Curr Oncol Rep; 2012 Apr; 14(2):129-38. PubMed ID: 22350330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mTOR pathway in hepatic malignancies.
    Bhat M; Sonenberg N; Gores GJ
    Hepatology; 2013 Aug; 58(2):810-8. PubMed ID: 23408390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR deregulation in oral cavity squamous cell carcinoma.
    Mastronikolis NS; Tsiambas E; Papadas TA; Fotiades PP; Papadas AT; Mastronikolis SN; Kastanioudakis I; Ragos V
    J BUON; 2017; 22(3):610-613. PubMed ID: 28730764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.
    Zhang S; Zhou YF; Cao J; Burley SK; Wang HY; Zheng XFS
    Cancer Res; 2021 Nov; 81(22):5652-5665. PubMed ID: 34429326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR inhibitor for the treatment of hepatocellular carcinoma.
    Kudo M
    Dig Dis; 2011; 29(3):310-5. PubMed ID: 21829022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Roles of mTOR in ageing and longevity].
    Hara K
    Nihon Rinsho; 2016 Sep; 74(9):1479-1484. PubMed ID: 30557480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.
    Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA
    Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
    Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
    PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin.
    Du W; Gerald D; Perruzzi CA; Rodriguez-Waitkus P; Enayati L; Krishnan B; Edmonds J; Hochman ML; Lev DC; Phung TL
    Lab Invest; 2013 Oct; 93(10):1115-27. PubMed ID: 23938603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.